Despite a challenging year for IPOs, the biotechnology sector is experiencing a significant surge, with numerous companies successfully going public. This trend stands in contrast to other industries facing market volatility and interest rate hikes. While the active biotech IPO market presents opportunities, historical data from the 2020 class shows that picking winners remains a difficult task, with many companies failing to deliver positive returns.
Key drivers for this biotech boom include increased M&A activity by large pharmaceutical companies and the rise of promising therapeutic areas like GLP-1 drugs. Investors are advised to exercise caution, focusing on companies with strong pipelines, experienced management, and a clear understanding of the drug development lifecycle, or to consider investing in the broader sector through ETFs and service providers.
In a year marked by a sluggish initial public offering (IPO) market, the biotechnology sector has emerged as a surprising outlier, defying broader economic headwinds. While many industries hesitate to go public, a significant number of biotech firms have successfully navigated the IPO landscape, raising substantial capital and signaling a robust appetite for innovation within the sector.
This surge in biotech IPOs comes at a time when other prominent companies, including OpenAI and data center firms like Airtrunk and Firmus, have either withdrawn their IPO plans or postponed their debuts due to factors such as rising interest rates and market volatility. Even smart ring maker Oura and home insurance firm Bamboo have put their public offerings on hold. Meanwhile, IPO hopeful Nscale faces pressure to significantly cut its valuation.
However, for biotechnology, the narrative is different. Since August, 16 companies have debuted on U.S. markets, with 11 of them being biotech firms. This year, a total of 26 biotech companies have gone public in the U.S., more than double the count from 2025 and the highest annual figure since 2021. With at least four more offerings in the pipeline, the sector's momentum appears poised to continue.
Despite the active IPO calendar, investors are cautioned to tread warily. A CNBC review of the 2020 biotech IPO class revealed a stark reality: only 16% of these companies have delivered positive returns, while a staggering 44% have seen their value plummet by 90% or more. An equivalent investment across the entire 2020 biotech IPO cohort would have resulted in a loss of over 25% as of Friday.
The Driving Forces Behind Biotech's IPO Boom
Several factors are contributing to this biotech IPO surge. According to Avery Marquez, director of investment strategies at Renaissance Capital, a pickup in mergers and acquisitions (M&A) by large pharmaceutical companies and the emergence of hot markets, such as GLP-1 drugs, have fueled this increased activity. Furthermore, the biotech sector often exhibits insulation from broader market headwinds, as its stock performance is frequently tied to company-specific news, such as clinical trial data or breakthroughs in specific health indications.
Biotech IPOs also benefit from a structural advantage: time. Their typically lower capital requirements and more specialized investor interest can lead to a streamlined bookbuilding and roadshow process, often completing within a week – a timeline rarely seen in other industries. Renaissance Capital anticipates that new biotech issues will remain steady through the end of the year and into 2027.
Lessons from the 2020 Biotech IPO Class
The history of biotech IPOs, particularly the class of 2020, offers valuable insights for investors navigating the current landscape. Back then, biotech IPOs were also in vogue, propelled by abundant capital from low interest rates, massive market liquidity, and the heightened focus on healthcare due to the Covid-19 pandemic.
While the current rally seems driven by advances in AI and deal-making, the 2020 bull market provides relevant lessons. CNBC's analysis of 75 biotech companies that went public in 2020 found that while 17 were acquired, only four received cash offers above their IPO prices. Many biotech acquisitions involve contingent value rights, which can tie payouts to future trial or commercial milestones, forcing investors into lengthy waiting periods.
The Good: Revolution Medicines
A standout performer from the 2020 cohort is Revolution Medicines. This oncology-focused company, which went public in February 2020, raised approximately $273 million. It has since secured significant funding through its acquisition of EQRx and a commitment from Royalty Pharma. In August, the company received FDA approval for its pancreatic cancer drug, Rasonque. Despite trading below $50 for an extended period, its stock has seen substantial growth, delivering approximately a 1,000% return as of Friday.
The Bad: LeonaBio (formerly Athira Pharmaceuticals)
On the other end of the spectrum is LeonaBio, formerly Athira Pharmaceuticals. Down 97% since its IPO, the company raised over $200 million for a central nervous system disorder treatment. However, its journey has been marred by the former CEO's resignation following an investigation into altered academic research, multiple failed clinical trials for its lead product, and a subsequent corporate pivot and licensing deal.
The Ugly: Codiak Biosciences
The most cautionary tale is that of Codiak Biosciences, which experienced a dramatic collapse. This development-stage biotech, focused on exosome-based therapeutics, went public in October 2020. By August 2022, it began laying off employees and pausing programs. The company ultimately filed for bankruptcy protection in March 2023, leaving equity investors with nothing less than three years after its debut.
How Investors Can Navigate the Biotech IPO Landscape
For investors looking to capitalize on the biotech boom without the extreme risks associated with individual drug developers, investing in companies that provide the industry's essential services – the 'picks and shovels' – is a strategic approach. These companies benefit from the sector's growth without being tied to the success or failure of a single drug.
ETFs like the iShares Biotechnology ETF (IBB) have shown strong performance, up 35% in 2026 and 28% in 2025. Analysts also recommend companies like IQVIA and Danaher. Veeva Systems, a provider of cloud-based software for the life sciences industry, is another attractive option, supporting companies throughout the entire product lifecycle. Its expanded partnership with IQVIA and upcoming investor day on November 5th are key points of interest.
For those willing to invest directly in biotech IPOs, Renaissance Capital advises considering:
- Phase of the lead product: Understand the stage of development and the associated time horizon.
- Breadth of the pipeline: A diverse pipeline reduces reliance on a single drug.
- Total Addressable Market (TAM): Assess the market size for the potential treatment.
- Unmet need: Does the drug address a critical gap in medical care?
- Management experience: Look for teams with a proven track record in drug development and commercialization.
- Established investors: The backing of reputable investors can be a positive indicator.
Investing in biotech IPOs can be akin to buying a lottery ticket; the potential for extraordinary gains exists, but so does the risk of significant losses. While the biotech IPO market may be open, historical data suggests that success is far from guaranteed. Investors are urged to look beyond the IPO momentum and conduct thorough due diligence, preparing for a long and often uncertain path to commercial success.
Disclaimer: This content is provided for informational purposes only and does not constitute financial, investment, tax, or legal advice. Consult with a qualified financial advisor before making any investment decisions.
